Review Article
Effects of Systemic or Local Administration of Zoledronate on Implant Osseointegration: A Preclinical Meta-Analysis
Table 1
Characteristics of enrolled studies.
| Studies | Animals | Group | ZOL dosage and route, or concentration | Implant | FU time | Number | Size | Site | Type | Coating |
| Ayan et al. [8] | Male rabbits | 1: control | 9 | 0.1 mg/kg IV | Tibia | Titanium screw | No | 4 weeks | 2: ZOL | Single dose |
| Cardemil et al. [9] | Female rats | 1: control (OVX) | 28 | 0.1 mg/kg IV | Tibia | Titanium screw | No | 4 weeks | 2: ZOL | Single dose |
| Carvas et al. [10] | Male rabbits | 1: control (GC) | 6 | 0.1 mg/kg IV | Tibia | Titanium screw | No | 18 weeks | 2: ZOL | Single dose |
| Chen et al. [11] | Female rats | 1: control (OVX) | 12 | 0.1 mg/kg IV | Tibia | Titanium rod | HA | 12 weeks | 2: ALN | Single dose | 3: SR | | 4: ZOL | |
| Dikicier et al. [12] | Female rats | 1: control (OVX) | 12 | 0.04 mg/kg IV | Tibia | Titanium screw | No | 8 weeks | 2: ZOL | 6 doses |
| Li et al. [13] | Female rabbits | 1: control (OVX) | 6 | 0.1 mg/kg SC | Tibia | Titanium screw | HA | 8 weeks | 2: ZOL | 3 doses |
| de Oliveira et al. [14] | Male rats | 1: control | 3 | 0.0075 mg/kg SC | Tibia | Titanium | No | 4 weeks | 2: ZOL | 3 doses |
| Qi et al. [15] | Female rabbits | 1: control (OVX) | 8 | 0.1 mg/kg SC | Tibia | Titanium screw | HA | 12 weeks | 2: local ZOL | 4 doses | 3: systemic ZOL | | 4: local and systemic ZOL | |
| Yaman et al. [16] | Male rats | 1: control | 7 | 0.1 mg/kg IV | Tibia | Titanium screw | HA | 12 weeks | 2: ZOL | 3 doses |
| Yildiz et al. [17] | Female rabbits | 1: control (OVX) | 12 | 0.1 mg/kg IV | Tibia | Titanium screw | Resorbable blast media | 8 weeks | 2: ZOL | Single dose |
| Blazsek et al. [18] | Female rats | 1: control | 5 | 0.6 mg/kg IP | Tail vertebra | Titanium screw | No | 6 weeks | 2: ZOL | 3 doses |
| von Knoch et al. [19] | Rabbits | 1: control | 12 | 0.015 mg/kg IV | Femur | Titanium cylinder | Fiber metal mesh | 12 weeks | 2: ZOL | Single dose |
| Arnoldi et al. [20] | Rabbits | 1: control | 6 | 1 μg/ml | Femur | Titanium screw | No | 10 days | 2: ZOL |
| Miettinen et al. [21] | Male rats | 1: control | 7 | 20 μg/ml | Femur | Titanium | No | 4 weeks | 2: ZOL |
| Gao et al. [22] | Female rats | 1: control (OVX) | 10 | 1 mg/ml | Tibia | Titanium | HA | 12 weeks | 2: ZOL |
| Stadlinger et al. [23] | Female rats | 1: control (OVX) | 8 | 8.5 μg/implant | Tibia | Titanium | No | 4 weeks | 2: ZOL |
| Ying et al. [24] | Female rats | 1: control (OVX) | 10 | 30 μg/implant | Tibia | Titanium cylinder | No | 12 weeks | 2: ZOL |
| Pyo et al. [25] | Female rats | 1: control (OVX) | 10 | 8 μg/ml | Tibia | Titanium screw | No | 8 weeks | 2: ZOL | 80 μg/ml | | 800 μg/ml |
| Sörensen et al. [26] | Rats | 1: control | 10 | 50 μg/implant | Tibia | Calcium phosphate bone cement | No | 3 weeks | 2: ZOL |
| Bobyn et al. [27] | Dogs | 1: control | 5 | 0.2 mg/ml | Femur | Tantalum | HA | 1 year | 2: ZOL |
|
|
ZOL: zoledronate; FU: follow-up; GC: glucocorticoid; HA: hydroxyapatite; ALN: alendronate; SR: strontium ranelate; SC: subcutaneous; IP: intraperitoneal.
|